Should we catch this falling knife after today’s 60% slump?

Does this stock’s 60% slump offer the perfect buying opportunity?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Accrol (LSE: ACRL) has only been a public company for 11 months, but during this time the business has made a considerable impact on the market. 

Initially, the company’s outlook appeared bright. Demand for its paper products, which includes toilet paper, kitchen towels and facial tissues was rising with revenue for the year to April 30 up 14.2% year-on-year and EBITDA up 6.8% to £16.1m. A 4.3% dividend yield was also on offer. 

Unfortunately, two months after publishing its figures for the year to April, the company stunned the market by warning on profits, announcing a previously undisclosed legal battle with the Health and Safety Executive (HSE) and suspending its shares. 

From bad to worse 

Since the suspension, the company’s prospects have gone from bad to worse. It pleaded guilty to a single health and safety regulatory offence arising out of an incident whereby an employee sustained a severe injury to the top of his right index finger. Fines from this incident could be between £550,000 and £2.9m. 

Meanwhile, the cost of the pulp the company uses in its products has jumped by nearly 41% since the beginning of the year, and Accrol has struggled to pass higher prices on to customers — a sudden reversal from the group’s past cash generation. 

With a hefty legal bill to pay, costs spiralling and margins contracting, it has been forced to ask shareholders for more cash to keep the lights on. Today, along with the lifting of its suspension, it announced that it is planning to raise £18m by way of a placing to meet working capital requirements at a 60% discount to the pre-suspension price. The company is placing 36m new shares at 50p. 

Is the outlook improving? 

Accrol’s management believes that the £18m placing will be enough to return the company to business as usual. The good news is that some customers are now accepting price hikes, which has taken some pressure off the firm. 

As well as reinforcing the balance sheet and hiking prices, management is also looking to cut costs by around 6% by reducing the employee headcount by 89 and cutting the number of products offered. These efforts are expected to return the business to profit on an EBITDA basis for the year ending April 2019.

So, it has a plan in place to get back to growth and profitability. However, I think it’s going to take a lot more work for Accrol to regain investors’ trust in the business. The firm has effectively imploded over the past six months, and the speed of the implosion has been staggering.

What’s more concerning is the way management has treated investors. There was no prior disclosure of the HSE investigation before the suspension, and in a trading update published on September 7, it made no mention of the rising price of pulp compressing margins, even though today management claimed that these costs have been proving to be a headwind since the beginning of the year. 

The bottom line

Overall, I’m not buying Accrol after today’s declines. The firm’s performance since it became a public company has been extremely disappointing, and it looks as if the business is going to struggle to return to growth in the next few years. There are better buys out there. 

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »